Longterm blood cell counts after intraoperative radiotherapy with or without whole breast radiotherapy in breast cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12014-e12014
Author(s):  
Elena Sperk ◽  
Cornelia Wersal ◽  
Christel Weiss ◽  
Anke Keller ◽  
Anette Kipke ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Blood Cell ◽  
Cancer Patients ◽  
Cell Lines ◽  
Breast Cancer Patients ◽  
Breast Radiotherapy ◽  
Cell Counts ◽  
Blood Cell Counts ◽  
Whole Breast Radiotherapy

e12014 Background: After radiotherapy changes in blood cell counts (BCC) can be seen. Leukocytopenia may have a negative impact on the immune system, outcome and quality of life of breast cancer survivors. No reports on changes of the three blood cell lines (leukocytes=WBC, erythrocytes=RBC, thrombocytes=PLT) after IORT w/o whole breast radiotherapy (WBRT) in breast cancer patients have been reported. Methods: 256 patients had IORT during breast conserving surgery. In 198 patients WBRT (46-50Gy/2Gy) + IORT (20Gy) and in 58 patients IORT as accelerated partial breast irradiation=APBI (20Gy) was given. Preoperative BCC were used as baseline. In 214 patients BCC were available after 1-90 days, in 139 during the 1st year, in 86 in the 2nd, in 66 in the 3rd, in 51 in the 4th and in 34 in the 5th year of follow-up. Dunnett-tests were used to calculate adjusted p-values (p<0.05=significant). Results: After IORT/WBRT a decrease of WBC was seen during the 1st year. Afterwards no changes were seen. After IORT APBI no changes were seen during 5 years follow-up. RBC was decreased at all time points after IORT/WBRT, and through the 1st year after IORT APBI. PLT decreased during the 1st year and stayed low during 5 years after IORT/WBRT. No changes in PLT were seen after IORT APBI. Hemoglobin (HGB) decreased after 3 months, during the 1st and 5th year after IORT/WBRT. After IORT APBI, HGB decreased only during the 1st year and stayed stable during follow-up. Conclusions: Decreases of all blood cell lines were seen at least transiently after IORT/WBRT. PLT and RBC stayed decreased. After IORT APBI, HGB and RBC decreased only during the 1st year and WBC and PLT remained stable during the whole follow-up. [Table: see text]

scholarly journals Onset of fatigue in breast cancer patients: correlation with serum cytokine levels, and blood cell counts

2016 ◽  
Vol 27 ◽  
pp. iv122
Author(s):  
M. Santoro ◽  
E. Iuliano ◽  
M. Luci ◽  
A. Perricelli ◽  
A. Pomillo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Blood Cell ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Serum Cytokine ◽  
Cell Counts ◽  
Blood Cell Counts ◽  
Cytokine Levels

Acute side effects of intraoperative electron radiotherapy of breast cancer.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 112-112
Author(s):  
Edwin Boelke ◽  
Wilfried Budach ◽  
Wolfgang Janni ◽  
Karin Zwiefel ◽  
Freddy-Joel Njanang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Acute Toxicity ◽  
Intraoperative Radiotherapy ◽  
Breast Cancer Patients ◽  
Breast Radiotherapy ◽  
European Organization ◽  
Whole Breast Radiotherapy ◽  
Acute Side Effects

112 Background: Intraoperative boost irradiation as part of breast-conserving therapy is a perfect method to adequately capture the high risk tumor relapse area. The most homogeneous dose distribution is achieved with electrons. Intraoperative radiotherapy (IOERT) as a boost for breast cancer releases a high single dose of radiation to the breast tissue; therefore acute toxicity is of particular attention. To date there is only inadequate information available on breast cancer patients treated with IORT using electrons applied as a boost. We therefore analyzed the acute toxicity after radiotherapy with 10 Gy as a boost with a minimum follow-up of 3 months. Methods: A total of 69 patients treated with IOERT (10Gy with 5, 7 and 9 MeV electrons) with a dedicated robotic linac (NOVAC 7, New Radiant Technology, Aprilia, Italy) to the tumor bed during breast-conserving surgery as a boost followed by whole-breast radiotherapy (WBRT, 50.4 Gy; 1.8 Gy per fraction) were included in this study. All patients underwent a retrospective follow-up (median, 8 months; range 1-17 months) regarding acute side effects within the first three months. Toxicities were documented using the common toxicity criteria (CTC 4.0 of the European Organization for Research and Treatment of Cancer). Results: The IOERT was well tolerated. As a side effect there was one patient with seroma. Two patients developed chronic pain in the irradiated breast. Two patients developed a secondary wound healing. The remaining patients did not develop any grade 3 or 4 side effects. The observed toxicity rates were not influenced by age, tubus size, electron energy or systemic therapy. Conclusions: After IOERT of the breast using electrons we did not find any unexpected acute toxicity rates.

scholarly journals Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients

2020 ◽  
Vol 27 (9) ◽  
pp. 3402-3411 ◽  
Author(s):  
Julia E. C. van Steenhoven ◽  
Anne Kuijer ◽  
Marissa C. van Maaren ◽  
Marleen Roos ◽  
Sjoerd G. Elias ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Regional Recurrence ◽  
Breast Cancer Patients ◽  
Breast Radiotherapy ◽  
Systemic Treatments ◽  
Whole Breast Radiotherapy

scholarly journals Associations between absolute neutrophil count and lymphocyte-predominant breast cancer

2019 ◽  
Author(s):  
Chang Ik Yoon ◽  
So Eun Park ◽  
Yoon Jin Cha ◽  
Soong June Bae ◽  
Chi Hwan Cha ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Blood Cell ◽  
Peripheral Blood ◽  
Immune Cell ◽  
Laboratory Data ◽  
Peripheral Blood Cell ◽  
Cell Mediated Immunity ◽  
Breast Cancer Patients ◽  
Cell Counts ◽  
Blood Cell Counts

AbstractTumor-infiltrating lymphocytes (TILs) might be associated with host-cell mediated immunity, which could be partly reflected by peripheral blood cell counts. We aimed to investigate whether peripheral blood cell counts are associated with TILs in breast cancer. Between August 2016 and July 2018, we evaluated the percentage of stromal TILs in breast cancer patients who underwent primary surgery, using the standardized methodology proposed by the international TIL Working Group. Lymphocyte-predominant breast cancer (LPBC) was defined as tumors having high TIL levels (≥ 50%). Peripheral blood cell counts including absolute neutrophil counts (ANC), absolute lymphocyte counts (ALC) and neutrophil-to-lymphocyte ratio (NLR) was obtained from pretreatment laboratory data. Of the 684 patients, 99 (17.2%) had LPBC, and 478 (82.8%) had non-LBPC. In a comparison of 3 markers of peripheral blood counts, LPBC had a significantly lower mean ANC than non-LPBC (3,330 vs. 3,660; P=0.004), but the other means were not different. Decreasing ANC was an independent clinical factor in predicting LPBC (OR: 0.736, 95% CI: 0.591-0.917; P=0.004). Low peripheral ANC might be linked with LPBC, supporting the hypothesis that systemic immune cell counts might be associated with the tumor-immune microenvironment.

Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy

2018 ◽  
Vol 35 (7) ◽  
Author(s):  
Michela Dispinzieri ◽  
Eliana La Rocca ◽  
Elisabetta Meneghini ◽  
Alba Fiorentino ◽  
Laura Lozza ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document